Quintanilha, Julia C. F.
Liu, Yingmiao
Etheridge, Amy S.
Yazdani, Akram
Kindler, Hedy L.
Kelly, William Kevin
Nixon, Andrew B.
Innocenti, Federico
Clinical trials referenced in this document:
Documents that mention this clinical trial
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)
https://doi.org/10.1007/s10456-021-09799-1
Documents that mention this clinical trial
Plasma levels of angiopoietin-2, VEGF-A, and VCAM-1 as markers of bevacizumab-induced hypertension: CALGB 80303 and 90401 (Alliance)
https://doi.org/10.1007/s10456-021-09799-1
Funding for this research was provided by:
National Cancer Institute of the National Institutes of Health (U10CA180821, UG1CA233373)
National Cancer Institute of the National Institutes of Health (U24CA196171, UG1CA233253, UG1CA233337)
Foundation for the National Institutes of Health (UG1CA233327)
Article History
Received: 2 February 2021
Accepted: 15 May 2021
First Online: 24 May 2021
Declarations
:
: JCFQ and FI are coinventors of a patent application, serial number 16/932,002. FI is an advisor for Emerald Lake Safety. These relationships have been disclosed to and are under management by UNC-Chapel Hill.
: All trials were conducted in accordance with recognized ethical guidelines. The study was performed in accordance with the Declaration of Helsinki and was approved by the local IRB.
: All participants provided written informed consent for sample collection and analysis.